Skip to main content

05.11.2015 | Original Paper | Ausgabe 8/2016 Open Access

The European Journal of Health Economics 8/2016

Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain

The European Journal of Health Economics > Ausgabe 8/2016
Manel Mata-Cases, Marc Casajuana, Josep Franch-Nadal, Aina Casellas, Conxa Castell, Irene Vinagre, Dídac Mauricio, Bonaventura Bolíbar
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s10198-015-0742-5) contains supplementary material, which is available to authorized users.
Manel Mata-Cases and Marc Casajuana wrote the manuscript and contributed equally to this study.


We estimated healthcare costs associated with patients with type 2 diabetes compared with non-diabetic subjects in a population-based primary care database through a retrospective analysis of economic impact during 2011, including 126,811 patients with type 2 diabetes in Catalonia, Spain. Total annual costs included primary care visits, hospitalizations, referrals, diagnostic tests, self-monitoring test strips, medication, and dialysis. For each patient, one control matched for age, gender and managing physician was randomly selected from a population database. The annual average cost per patient was €3110.1 and €1803.6 for diabetic and non-diabetic subjects, respectively (difference €1306.6; i.e., 72.4 % increased cost). The costs of hospitalizations were €1303.1 and €801.6 (62.0 % increase), and medication costs were €925.0 and €489.2 (89.1 % increase) in diabetic and non-diabetic subjects, respectively. In type 2 diabetic patients, hospitalizations and medications had the greatest impact on the overall cost (41.9 and 29.7 %, respectively), generating approximately 70 % of the difference between diabetic and non-diabetic subjects. Patients with poor glycaemic control (glycated haemoglobin >7 %; >53 mmol/mol) had average costs of €3296.5 versus €2848.5 for patients with good control. In the absence of macrovascular complications, average costs were €3008.1 for diabetic and €1612.4 for non-diabetic subjects, while its presence increased costs to €4814.6 and €3306.8, respectively. In conclusion, the estimated higher costs for type 2 diabetes patients compared with non-diabetic subjects are due mainly to hospitalizations and medications, and are higher among diabetic patients with poor glycaemic control and macrovascular complications.

Unsere Produktempfehlungen

Neuer Inhalt


e.Med Interdisziplinär


Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen! 

Supplementary material 1 (DOCX 97 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 8/2016

The European Journal of Health Economics 8/2016 Zur Ausgabe